(Reuters) – UK’s Medicines and Healthcare products Regulatory Agency (MHRA) said on Tuesday it had approved Merck’s therapy to treat a rare lung condition called pulmonary arterial hypertension.
The therapy, sotatercept, received approval in the United States in March 2024 and is sold under the brand name Winrevair.
Patients with pulmonary arterial hypertension have high blood pressure in the vessels that supply the lungs. It is a rare and serious condition that can damage the right side of the heart.
The MHRA said the treatment can be used in combination with other medicines in adults with moderate or marked limitations of physical activity to help improve their exercise capacity.
Don't miss out on any breaking news or insightful opinions!
Subscribe to our free newsletter and stay updated on the go!
By submitting this form, you are consenting to receive marketing emails from: Global Banking & Finance Review. You can revoke your consent to receive emails at any time by using the SafeUnsubscribe® link, found at the bottom of every email.
(Reporting by Bhanvi Satija in Bengaluru; Editing by Anil D’Silva)
